188 related articles for article (PubMed ID: 16631419)
1. Binding mode of novel 1-substituted quinazoline derivatives to poly(ADP-ribose) polymerase-catalytic domain, revealed by X-ray crystal structure analysis of complexes.
Matsumoto K; Kondo K; Ota T; Kawashima A; Kitamura K; Ishida T
Biochim Biophys Acta; 2006 May; 1764(5):913-9. PubMed ID: 16631419
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling.
Ruf A; de Murcia G; Schulz GE
Biochemistry; 1998 Mar; 37(11):3893-900. PubMed ID: 9521710
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis.
Ruf A; Rolli V; de Murcia G; Schulz GE
J Mol Biol; 1998 Apr; 278(1):57-65. PubMed ID: 9571033
[TBL] [Abstract][Full Text] [Related]
5. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
6. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity.
Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B
Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Karlberg T; Hammarström M; Schütz P; Svensson L; Schüler H
Biochemistry; 2010 Feb; 49(6):1056-8. PubMed ID: 20092359
[TBL] [Abstract][Full Text] [Related]
8. Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Hattori K; Kido Y; Yamamoto H; Ishida J; Kamijo K; Murano K; Ohkubo M; Kinoshita T; Iwashita A; Mihara K; Yamazaki S; Matsuoka N; Teramura Y; Miyake H
J Med Chem; 2004 Aug; 47(17):4151-4. PubMed ID: 15293985
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2.
Oliver AW; Amé JC; Roe SM; Good V; de Murcia G; Pearl LH
Nucleic Acids Res; 2004; 32(2):456-64. PubMed ID: 14739238
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Quinazoline-2,4(1
Zhou J; Ji M; Wang X; Zhao H; Cao R; Jin J; Li Y; Chen X; Sheng L; Chen X; Xu B
J Med Chem; 2021 Nov; 64(22):16711-16730. PubMed ID: 34748333
[TBL] [Abstract][Full Text] [Related]
11. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors.
Iwashita A; Hattori K; Yamamoto H; Ishida J; Kido Y; Kamijo K; Murano K; Miyake H; Kinoshita T; Warizaya M; Ohkubo M; Matsuoka N; Mutoh S
FEBS Lett; 2005 Feb; 579(6):1389-93. PubMed ID: 15733846
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase.
Kinoshita T; Nakanishi I; Warizaya M; Iwashita A; Kido Y; Hattori K; Fujii T
FEBS Lett; 2004 Jan; 556(1-3):43-6. PubMed ID: 14706823
[TBL] [Abstract][Full Text] [Related]
13. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis.
Costantino G; Macchiarulo A; Camaioni E; Pellicciari R
J Med Chem; 2001 Nov; 44(23):3786-94. PubMed ID: 11689065
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, cytotoxic evaluation and molecular docking study of novel quinazoline derivatives as PARP-1 inhibitors.
Amin KM; Anwar MM; Kamel MM; Kassem EM; Syam YM; Elseginy SA
Acta Pol Pharm; 2013; 70(5):833-49. PubMed ID: 24147361
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors.
Zhao H; Ji M; Cui G; Zhou J; Lai F; Chen X; Xu B
Bioorg Med Chem; 2017 Aug; 25(15):4045-4054. PubMed ID: 28622906
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide.
Bell CE; Eisenberg D
Biochemistry; 1996 Jan; 35(4):1137-49. PubMed ID: 8573568
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3.
Sherstyuk YV; Ivanisenko NV; Zakharenko AL; Sukhanova MV; Peshkov RY; Eltsov IV; Kutuzov MM; Kurgina TA; Belousova EA; Ivanisenko VA; Lavrik OI; Silnikov VN; Abramova TV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892271
[TBL] [Abstract][Full Text] [Related]
18. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken.
Ruf A; Mennissier de Murcia J; de Murcia G; Schulz GE
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7481-5. PubMed ID: 8755499
[TBL] [Abstract][Full Text] [Related]
19. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
20. Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications.
Tao Z; Gao P; Liu HW
J Am Chem Soc; 2009 Oct; 131(40):14258-60. PubMed ID: 19764761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
